Celularity Receives Nasdaq Notice Regarding Form 10-Q
Celularity (NASDAQ:CELU), a regenerative and cellular medicine company, announced receiving a notice from Nasdaq on August 21, 2025, regarding its failure to file the Q2 2025 Form 10-Q. This marks the company's second delayed quarterly filing, following the Q1 2025 Form 10-Q.
The company is currently non-compliant with Nasdaq Listing Rule 5250(c)(1), though this notice does not immediately affect CELU's listing status. Nasdaq has given Celularity until September 5, 2025 to update its compliance plan, with a final deadline of November 17, 2025 to file all delinquent reports.
Celularity (NASDAQ:CELU), società nel campo della medicina rigenerativa e cellulare, ha comunicato di aver ricevuto il 21 agosto 2025 una notifica da Nasdaq per il mancato deposito del modulo 10-Q relativo al secondo trimestre 2025. Si tratta del secondo ritardo nella presentazione dei trimestrali, dopo il 10-Q del primo trimestre 2025.
La società è attualmente non conforme alla Regola di quotazione Nasdaq 5250(c)(1), sebbene la notifica non incida immediatamente sullo stato di quotazione di CELU. Nasdaq ha concesso a Celularity tempo fino al 5 settembre 2025 per aggiornare il piano di conformità e ha fissato come termine finale il 17 novembre 2025 per depositare tutte le relazioni in arretrato.
Celularity (NASDAQ:CELU), una compañía de medicina regenerativa y celular, anunció que recibió una notificación de Nasdaq el 21 de agosto de 2025 por no presentar el formulario 10-Q del segundo trimestre de 2025. Esta es la segunda presentación trimestral retrasada de la compañía, tras el 10-Q del primer trimestre de 2025.
La empresa actualmente no cumple con la Norma de cotización de Nasdaq 5250(c)(1), aunque dicha notificación no afecta de inmediato al estado de cotización de CELU. Nasdaq ha dado a Celularity hasta el 5 de septiembre de 2025 para actualizar su plan de cumplimiento y estableció como fecha límite final el 17 de noviembre de 2025 para presentar todos los informes pendientes.
Celularity (NASDAQ:CELU), 재생 및 세포 의학 회사는 2025년 8월 21일 나스닥으로부터 2025년 2분기 분기보고서(폼 10-Q)를 제출하지 않았다는 통지를 받았다고 발표했습니다. 이는 2025년 1분기 10-Q에 이어 두 번째 분기보고서 지연입니다.
회사는 현재 나스닥 상장 규정 5250(c)(1)을 준수하지 않고 있으나, 이 통지는 즉시 CELU의 상장 상태에 영향을 미치지 않습니다. 나스닥은 Celularity에 준수 계획을 업데이트할 기한을 2025년 9월 5일까지 주었고, 모든 미제출 보고서를 제출할 최종 기한을 2025년 11월 17일로 정했습니다.
Celularity (NASDAQ:CELU), une société de médecine régénérative et cellulaire, a annoncé avoir reçu le 21 août 2025 un avis de Nasdaq concernant le non-dépôt du formulaire 10-Q du deuxième trimestre 2025. Il s'agit du deuxième dépôt trimestriel retardé de la société, après le 10-Q du premier trimestre 2025.
La société est actuellement non conforme à la règle de cotation Nasdaq 5250(c)(1), mais cet avis n'affecte pas immédiatement le statut de cotation de CELU. Nasdaq a accordé à Celularity jusqu'au 5 septembre 2025 pour mettre à jour son plan de conformité et a fixé au 17 novembre 2025 la date limite finale pour déposer tous les rapports en retard.
Celularity (NASDAQ:CELU), ein Unternehmen für regenerative und zelluläre Medizin, gab bekannt, dass es am 21. August 2025 eine Mitteilung von der Nasdaq wegen der Nicht-Einreichung des 10-Q-Berichts für das zweite Quartal 2025 erhalten hat. Dies ist die zweite verspätete Quartalsmeldung des Unternehmens, nach dem 10-Q für das erste Quartal 2025.
Das Unternehmen verstößt derzeit gegen die Nasdaq-Listing-Regel 5250(c)(1), wobei diese Mitteilung die Notierung von CELU nicht sofort beeinträchtigt. Nasdaq hat Celularity bis zum 5. September 2025 Zeit gegeben, seinen Compliance-Plan zu aktualisieren, und den 17. November 2025 als endgültige Frist gesetzt, um alle überfälligen Berichte einzureichen.
- None.
- Company failed to file both Q1 and Q2 2025 Form 10-Q reports on time
- Non-compliance with Nasdaq listing requirements
- Risk of potential delisting if compliance is not achieved by November 17, 2025
FLORHAM PARK, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company focused on addressing age-related and degenerative diseases, today announced that on August 21, 2025, Nasdaq notified the Company that it did not timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2025. Based on this latest notice, the Company is not in compliance with Listing Rule 5250 (c)(1), which requires the Company to timely file all required periodic financial reports with the Securities and Exchange Commission.
The Notice received from Nasdaq has no immediate effect on the listing or trading of the Company’s shares. Previously Nasdaq had granted the Company an exception until August 31, 2025 to file its Form 10-Q for the period ended March 31, 2025 (“Initial Delinquent Filing”) and the period ended June 30, 2025. Any additional Nasdaq exception to allow the Company to regain compliance will be limited to a maximum of 180 calendar days from the due date of the Initial Delinquent Filing or November 17, 2025. Nasdaq has provided the Company until September 5, 2025 to submit an update to its original plan to regain compliance.
The Company continues to work diligently to complete its Form 10-Q for the periods ended March 31, 2025 and June 30, 2025, after which the Company anticipates maintaining compliance with its SEC reporting obligations.
About Celularity
Celularity Inc. (Nasdaq: CELU) is a regenerative and cellular medicine company developing and commercializing advanced biomaterial products and cryopreserved allogeneic cell therapies, all derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies. For more information about Celularity and its cutting-edge regenerative medicine solutions, please visit www.celularity.com.
Forward Looking Statements
This press release includes “forward-looking statements” (as defined under Federal securities laws). These forward-looking statements include, without limitation, statements regarding: (i) our future sales or sales growth; (ii) our expectations for future financial results, including levels of net sales; (iii) our expectations regarding new products including our 510K products; and (iv) future demand for our products. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “could,” “continue,” “expect,” “improving,” “may,” “observed,” “potential,” “promise,” “should,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Celularity’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks,” and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including those risk factors set forth under the caption “Risk Factors” in Celularity’s annual report on Form 10-K and Form 10-K/A for the year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC) on May 8, 2025 and May 21, 2025, respectively, and other filings with the SEC. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Celularity does not presently know, or that Celularity currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect Celularity’s current expectations, plans, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing Celularity’s views as of any subsequent date, and Celularity undertakes no obligation to update forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
Carlos Ramirez
Senior Vice President, Celularity Inc.
Carlos.ramirez@celularity.com
FAQ
What is the deadline for Celularity (CELU) to file its delayed quarterly reports?
Will Celularity (CELU) be delisted from Nasdaq due to delayed quarterly filings?
What Nasdaq rule did Celularity (CELU) violate?
When must Celularity (CELU) submit its updated compliance plan to Nasdaq?
